explore -WSS

explore

author：comprehensive 2025-09-30 01:02:28 - browse：86616

Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system.

The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Lawmakers consider Medicare pay reforms for doctors

WSS

STAT Summit: How a Chicago ER doctor tackles gun violence

The EU Joint Clinical Assessment needs to live up to its promise

Giant panda gives birth to squirming, squealing healthy twin girls at South Korean theme park

Eli Lilly expects to double planned employment in Boston center

STAT Readout Newsletter: Today's biggest biotech updates

Cuban government calls US nuclear submarine stop a 'provocative escalation'

knowledge

explore

focus

The cancer drug shortage isn’t new — and neither are the solutions

Impact of Dobbs ruling felt at reproductive medicine meeting

Medical leaders decry Supreme Court decision on affirmative action

The debate over Covid

Hepatitis C has a cure — but many Americans still lack access to it

STAT Summit: GSK CEO on pharma giant's new direction

Jerome Adams on the need for new antivirals for Covid

CEOs share strategies for surviving biotech slump

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Vermont grapples with historic flooding as more rainstorms head for Northeast

Wikipedia

STAT Readout Newsletter: Today's biggest biotech updates

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

Pharmacists can make shortage drugs, but at what cost?

Kerry to visit Beijing for climate talks amid efforts to revive relations between US and China

Pharmacists can make shortage drugs, but at what cost?

Sickle cell gene therapy cures need to be accessible in Africa

explore

Wikipedia

hotspot

focus